The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The community screening programme charts an effective, affordable framework for TB control in the Canadian province of ...

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

With the new funding, Research Grid plans to invest in research and development, creating more AI automation and expanding its engineering teams. Credit: Collagery / Shutterstock. Research Grid has ...

Oak Hill Bio and Chiesi have enrolled the first European patient in a Phase IIb study for OHB-607, to prevent BPD in infants.

Allurion expects to complete the US approval filling next year, with data from its pivotal trial. Image credit: ichefboy / ...

Novo Nordisk has reported positive outcomes from part one of the ESSENCE trial of semaglutide 2.4 mg in treating MASH and ...

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

The R3 Vascular investigational device exemption will be used to launch a pivotal trial of its treatment for peripheral arterial disease.

Sutro Biopharma has begun the REFRαME-P1 trial of Luvelta to treat paediatric patients with a type of acute myeloid leukaemia (AML).

Endevica Bio has launched a new spin-off company, Abisati, to accelerate its obesity candidate into clinical trials.